The Food and Drug Administration (FDA) has not published any of the cannabinoid classification lists or packaging guidance Congress required it to release earlier this year, according to a new congressional analysis issued just two weeks before the first phase of sweeping federal hemp restrictions takes effect.
An October 28 report from the Congressional Research Service (CRS) confirms that the agency has yet to fulfill requirements established under a federal law enacted in November 2025, despite a 90-day deadline that expired in February.
Under Public Law 119-37, the FDA was directed to consult with other federal agencies and publish three separate lists identifying cannabinoids that can occur naturally in marijuana plants, THC-class cannabinoids known to occur naturally, and other cannabinoids with effects similar to THC or marketed as having similar effects. The law also required the agency to provide additional clarification regarding the definition of a product’s “container,” a distinction that will determine how certain THC limits are applied.
“As of the date of the publication of this Legal Sidebar, FDA has not published any of these items,” states the CRS report.
The outstanding requirements come as major changes to federal hemp law are approaching. Congress initially scheduled the new definition of hemp to take effect November 12, 2026, but legislation approved in September postponed most provisions until December 11.
However, the September legislation preserved the original November 12 implementation date for restrictions on products containing cannabinoids that cannot be produced naturally by the cannabis plant.
Beginning on that date, products containing those cannabinoids will no longer qualify as hemp under federal law and will be subject to controlled substance restrictions to the extent they fall under the federal definitions of marijuana or THC.
One example highlighted by congressional researchers is THC-O, a cannabinoid produced through chemical processing that does not naturally occur in marijuana plants.
The CRS report also highlights a longstanding legal disagreement over how federal law treats these substances. In 2023, the Drug Enforcement Administration (DEA) determined that THC-O was a Schedule I controlled substance because it could only be produced synthetically.
However, in September 2024, the U.S. Court of Appeals for the Fourth Circuit reached a different conclusion in Anderson v. Diamondback Investment Group, finding that THC-O derived from cannabis could qualify as federally legal hemp under the 2018 Farm Bill, provided it satisfied the law’s delta-9 THC concentration limit.
The new federal restrictions would establish a more explicit statutory exclusion for cannabinoids that cannot naturally occur in the plant, potentially resolving that disagreement for products covered by the amendment.
Additional restrictions scheduled for December 11 will substantially narrow the federal definition of hemp. These include replacing the existing 0.3% delta-9 THC threshold with a broader total THC standard, excluding products containing naturally occurring cannabinoids that were synthesized or manufactured outside the plant, and prohibiting final hemp-derived cannabinoid products containing more than 0.4 milligrams of combined total THC and similarly acting cannabinoids per container.
The FDA’s unpublished guidance is particularly relevant to these changes because the agency was specifically directed to identify which cannabinoids occur naturally and which have effects similar to THC. Those classifications could help manufacturers, retailers and regulators determine which products fall under the new federal restrictions.
The absence of the guidance does not automatically prevent the law from taking effect, but it leaves outstanding questions about how certain cannabinoids and product packaging will be classified.
Congressional researchers also note that lawmakers have introduced legislation to further delay or repeal the new restrictions, including H.R. 7024, H.R. 7010, S. 3686 and H.R. 6209.
For now, the November 12 restrictions remain scheduled to take effect, with the broader changes following December 11 unless Congress intervenes.
Related posts:

White House Reaffirms Trump’s Support for Marijuana Reform, Says Administration Continues Exploring ...

Federal Highway Safety Agency Plans First Marijuana-Focused Evaluation of Impaired-Driving Campaigns...








